Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and MetabolomicsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study examined how Zhuyang Tongbian Decoction (ZTD), a treatment for functional constipation (FC), affects the gut microbiome and related inflammatory markers. Researchers used 16S rRNA sequencing, metagenomics, and metabolomics to track changes in intestinal flora composition and microbiota metabolic function. They also measured fecal short-chain fatty acid (SCFA) levels and serum concentrations of TLR4, NF-κB, TNF-α, and IL-6 before and after treatment.
Who was studied?
The study included 40 patients with functional constipation, randomly divided into a control group (20 cases, treated with lactulose) and a treatment group (20 cases, treated with ZTD). Twenty healthy volunteers were also recruited during the same period, presumably for comparison. Sample sizes were small, consistent with the pilot nature of the study.
What were the most important findings?
The ZTD treatment group showed a significant increase in beneficial bacteria, including Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii (P < 0.05). Desulfobacterota and Ruminococcus were significantly reduced in the treatment group (P < 0.05). Fecal acetic and propionic acid levels, both short-chain fatty acids linked to anti-inflammatory commensal activity, were also affected by treatment, though the abstract text describing the exact direction and magnitude was cut off.
What are the greatest implications of this study?
The findings suggest ZTD may relieve functional constipation partly by reshaping the gut microbiota toward beneficial, SCFA-producing organisms such as Faecalibacterium prausnitzii while reducing potentially less favorable taxa. This points to a microbiome-mediated mechanism, possibly involving reduced inflammatory signaling through the TLR4/NF-κB pathway, as part of ZTD's therapeutic effect. As a pilot study with a small sample size, these results support further, larger trials to confirm the mechanism and clinical benefit.